{"filing":{"accession_number":"0001193125-26-302008","cik":"0001810560","ticker":"REVBW","company_name":"REVELATION BIOSCIENCES, INC.","form":"8-K","filing_date":"2026-07-13","report_date":null,"primary_document":"revb-20260710.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526302008/revb-20260710.htm"},"events":[{"id":17585,"run_id":15752,"accession_number":"0001193125-26-302008","anchor_item_number":"1.01","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"Revelation Biosciences adopted a stockholder rights plan (poison pill) on July 10, 2026, declaring a dividend distribution of one right per outstanding share and filing a Certificate of Designation for Series B Junior Participating Preferred Stock. The rights become exercisable if any person or group acquires 10% or more beneficial ownership without Board approval, entitling other shareholders to purchase shares at a discount as a defensive measure against hostile takeovers.","company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVBW","filing_date":"2026-07-13","form":"8-K","submitted_at":null,"items":[{"id":16115,"accession_number":"0001193125-26-302008","item_number":"1.01","item_title":"Entry Into A Material Definitive Agreement.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The Company adopted a stockholder rights plan (poison pill) on July 10, 2026, entering into a Rights Agreement with Continental Stock Transfer \u0026 Trust Co. This is a governance-related defensive measure designed to protect against hostile takeovers by triggering dilutive rights if any person acquires 10% or more of outstanding common stock without Board approval. While the filing is disclosed under Item 1.01 (Material Definitive Agreement), the substance is a governance action—a board-adopted anti-takeover mechanism—rather than a traditional M\u0026A transaction, debt issuance, or other financial event. The rights plan is material to investors as it affects voting control dynamics and potential acquisition scenarios.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T20:06:46.090545+00:00","company_name":"","ticker":null,"filing_date":""},{"id":16116,"accession_number":"0001193125-26-302008","item_number":"3.03","item_title":"Material Modification To Rights Of Security Holders.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"Revelation Biosciences adopted a stockholder rights plan (poison pill) on July 10, 2026, and declared a dividend distribution of one right per outstanding share. The rights become exercisable if a person or group acquires 10% or more beneficial ownership without Board approval, entitling other shareholders to purchase shares at a discount. This is a governance measure designed to protect against hostile takeovers and materially modifies shareholder rights, fitting the Item 3.03 disclosure category and the governance domain, though it does not fit a specific named governance event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T20:06:46.090545+00:00","company_name":"","ticker":null,"filing_date":""},{"id":16117,"accession_number":"0001193125-26-302008","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws, Change in Fiscal Year.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses adoption of a stockholder rights plan (poison pill) and filing of a Certificate of Designation for Series B Junior Participating Preferred Stock under Item 5.03. While this is a governance matter involving amendments to the company's capital structure, it does not fit the specific categories of exec_departure, exec_appointment, or exec_compensation. The rights plan is a material anti-takeover defense that would affect investor assessment of control and acquisition risk, making it a governance event that warrants disclosure but falls outside named governance categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T20:06:46.090545+00:00","company_name":"","ticker":null,"filing_date":""},{"id":16118,"accession_number":"0001193125-26-302008","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The Company announced adoption of a stockholder rights plan (poison pill) by its Board of Directors on July 10, 2026, with a dividend distribution of one right per outstanding share. This is a governance event designed to protect against hostile takeovers by triggering dilutive consequences if any person or group acquires 10% or more of outstanding common stock without Board approval. While not a specific named governance type (not an executive appointment, departure, or compensation matter), it is clearly a material governance action that would affect a reasonable investor's assessment of takeover risk and shareholder protections.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T20:06:46.090545+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16115,"accession_number":"0001193125-26-302008","item_number":"1.01","item_title":"Entry Into A Material Definitive Agreement.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The Company adopted a stockholder rights plan (poison pill) on July 10, 2026, entering into a Rights Agreement with Continental Stock Transfer \u0026 Trust Co. This is a governance-related defensive measure designed to protect against hostile takeovers by triggering dilutive rights if any person acquires 10% or more of outstanding common stock without Board approval. While the filing is disclosed under Item 1.01 (Material Definitive Agreement), the substance is a governance action—a board-adopted anti-takeover mechanism—rather than a traditional M\u0026A transaction, debt issuance, or other financial event. The rights plan is material to investors as it affects voting control dynamics and potential acquisition scenarios.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T20:06:46.090545+00:00","company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVBW","filing_date":"2026-07-13"},{"id":16116,"accession_number":"0001193125-26-302008","item_number":"3.03","item_title":"Material Modification To Rights Of Security Holders.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"Revelation Biosciences adopted a stockholder rights plan (poison pill) on July 10, 2026, and declared a dividend distribution of one right per outstanding share. The rights become exercisable if a person or group acquires 10% or more beneficial ownership without Board approval, entitling other shareholders to purchase shares at a discount. This is a governance measure designed to protect against hostile takeovers and materially modifies shareholder rights, fitting the Item 3.03 disclosure category and the governance domain, though it does not fit a specific named governance event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T20:06:46.090545+00:00","company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVBW","filing_date":"2026-07-13"},{"id":16117,"accession_number":"0001193125-26-302008","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws, Change in Fiscal Year.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses adoption of a stockholder rights plan (poison pill) and filing of a Certificate of Designation for Series B Junior Participating Preferred Stock under Item 5.03. While this is a governance matter involving amendments to the company's capital structure, it does not fit the specific categories of exec_departure, exec_appointment, or exec_compensation. The rights plan is a material anti-takeover defense that would affect investor assessment of control and acquisition risk, making it a governance event that warrants disclosure but falls outside named governance categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T20:06:46.090545+00:00","company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVBW","filing_date":"2026-07-13"},{"id":16118,"accession_number":"0001193125-26-302008","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The Company announced adoption of a stockholder rights plan (poison pill) by its Board of Directors on July 10, 2026, with a dividend distribution of one right per outstanding share. This is a governance event designed to protect against hostile takeovers by triggering dilutive consequences if any person or group acquires 10% or more of outstanding common stock without Board approval. While not a specific named governance type (not an executive appointment, departure, or compensation matter), it is clearly a material governance action that would affect a reasonable investor's assessment of takeover risk and shareholder protections.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T20:06:46.090545+00:00","company_name":"REVELATION BIOSCIENCES, INC.","ticker":"REVBW","filing_date":"2026-07-13"}]}